Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Completed
Midnight Pharma, LLC
Phase 2
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and
tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with
primary insomnia.
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Completed
Midnight Pharma, LLC
Phase 3
A polysomnography study to evaluate the effect, safety and tolerability of oral
administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep
efficiency and to assess the effects of different doses of ACT-078573 on other PSG
parameters.
Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Completed
U.S. Army Medical Research and Development Command
N/A
In recent years, there has been increased focus on cognitive side effects of sleep-inducing
medications that may contribute to unusual behavior during unexpected awakenings during the
night. Concerns regarding these side effects have led to a class Food and Drug Administration
(FDA) warning for all sleep-inducing medications. Almorexant is an experimental
sleep-inducing medication in a new class of medications that is being extensively developed
by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in
the brain that function with proteins called hypocretins. The goal of this study is to
evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep
aid) or placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
